Vermilion (VET) possesses solid growth attributes, which could help it handily outperform the market.
The mean of analysts' price targets for Vermilion (VET) points to a 29.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Canada's Vermilion Energy said on Thursday it will sell its United States assets for $120 million.
VET mentions that proceeds from the asset sale are intended to strengthen the company's balance sheet and improve its financial position.
Vermilion Energy's Q1 2025 results show a production increase to 103,115 boe/d, with healthy funds flow. Despite a 48% negative stock price return over the past two years, Vermilion's diversified production mitigates exposure to lower energy prices. The recent debt-financed acquisition has increased net debt, but the company's high-margin European natural gas production and hedges provide near-term protection.
Vermilion Energy, primarily a gas company, trades like an oil company, creating a valuation disconnect with potential fair value of $12 per share. Despite producing 74% of FFO from gas, Vermilion's stock is undervalued, trading near its 52-week low, while gas peers are at highs. Vermilion's recent acquisitions and European gas focus enhance profitability, with a manageable debt level and attractive 6% dividend yield.
Vermilion Energy Inc (NYSE:VET ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Myron Stadnyk - Chairman Tamar Epstein - General Counsel & Corporate Secretary Kyle Preston - VP of Investor Relations Averyl Schraven - Vice President, People & Culture Dion Hatcher - President & Chief Executive Officer Darcy Kerwin - Vice President of International and HSE Randy McQuaig - Vice President of North America Conference Call Participants Operator Good afternoon, ladies and gentlemen. Thank you for standing by.
Vermilion Energy (VET) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.01 per share a year ago.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Vermilion (VET) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vermilion (VET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.